DOI : 10.1055/s-00034924

Nuklearmedizin - NuclearMedicine

Ausgabe 02 · Volume 60 · April 2021 DOI: 10.1055/s-011-50684

Deutsche Gesellschaft für Nuklearmedizin
NuklearMedizin 2021 – digital
, 14.-17.04.2021

Prof. Dr. Michael Schäfers

L3
Schmidkonz, C; Distler, J; Treutlein, C; Atzinger, A; Prante, O; Ritt, P; Götz, TI; Bäuerle, T; Cordes, M; Köhner, M; Kuwert, T; Ramming, A; Schett, G; Bergmann, C: 68Ga-FAPI-04 PET/CT for molecular assessment of fibroblast activation and risk evaluation in systemic sclerosis-related interstitial lung disease
L4
Meyer, PM; Strauß, M; Becker, GA; Hesse, S; Bednasch, K; Ettrich, B; Zientek, F; Rullmann, M; Luthardt, J; Fischer, S; Patt, M; Barthel, H; Wünsch, B; Brust, P; Sabri, O: Increased sigma-1 receptor (S1R) availability and its association with depressive and cognitive symptoms in untreated patients with acute early onset unipolar depression (EO-UP): a (-)-F-18-Fluspidine PET study
L5
Voltin, C; Mettler, J; van Heek, L; Goergen, H; Müller, H; Baues, C; Keller, U; Meissner, J; Trautmann-Grill, K; Kerkhoff, A; Fuchs, M; Sasse, S; von Tresckow, B; Dietlein, M; Borchmann, P; Engert, A; Kobe, C; Bröckelmann, PJ: PET-based response assessment in Hodgkin lymphoma patients undergoing PD-1 blockade: data of the German Hodgkin Study Group NIVAHL trial for early unfavorable stages
L6
Seifert, R; Kersting, D; Sandach, P; Weber, M; Rischpler, C; Schmitz, C; Hüttmann, A; Reinhardt, C; von Tresckow, B; Dührsen, U; Schäfers, M; Herrmann, K: Interim FDG PET analysis performed by Neural Networks to predict the outcome of patients with aggressive B-cell lymphoma
L7
Blazhenets, G; Dreßing, A; Schroeter, N; Bormann, T; Thurow, J; Frings, L; Weiller, C; Hosp, JA; Meyer, PT: Altered regional cerebral glucose metabolism and its correlation with cognitive impairment in the subacute stage of COVID-19
L8
Feuerecker, B; Chantadisai, M; Allmann, A; Tauber, R; Allmann, J; Wurzer, A; Rauscher, I; Wester, HJ; Weber, WA; D’Alessandria, C; Eiber, M: Prä-therapeutische Dosimetrie von Lu-177-rhPSMA7.3 und Lu-177-PSMA-I&T bei Patienten mit metastasiertem kastrationsresistentem Prostatakarzinom (mCRPC)